Antibodies to combat melioidosis: bridging immune mechanisms with diagnostics and therapeutic potential
Rattachement africain : nl, ca, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE OF REVIEW: Melioidosis, caused by the Gram-negative soil bacterium Burkholderia pseudomallei , is a frequently fatal (sub)tropical infection with a substantial global burden. This review summarizes current insights into antibody-mediated immunity in melioidosis and its clinical potential. RECENT FINDINGS: Antibodies against B. pseudomallei polysaccharides and protein antigens promote bacterial clearance through opsonophagocytosis and complement activation, reducing intracellular spread. People who survive melioidosis develop broader and more durable antibody repertoires than nonsurvivors. Protective antibody responses vary by antigen class and are influenced by host factors, notably diabetes, a main risk factor for melioidosis. Diagnostic serology has advanced from low-performing indirect hemagglutination to single-antigen tests and multiplex platforms. Performance, however, is specimen-dependent, limited by cross-reactivity with related Burkholderia spp., and by cost and resource constraints in endemic settings. In preclinical models of melioidosis, monoclonal antibodies against B. pseudomallei confer passive protection and are being developed for prophylaxis, adjunctive therapy, and as platforms for antibody-antibiotic conjugates or vaccine design. SUMMARY: Antibody responses to key virulence factors correlate with disease course and are increasingly studied for diagnostic and therapeutic applications. This review aids in informing novel diagnostics and guide antibody-based therapies offering new directions for clinical management and prevention of this high-burden but underrecognized infection.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Antibodies to combat melioidosis: bridging immune mechanisms with diagnostics and therapeutic potential
- Date Crossref
- 01/12/2025
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Amsterdam Neuroscience pays non établi dans la noticeStructure de recherche
-
Institute of Infection and Immunity pays non établi dans la noticeStructure de recherche
-
Office of Infectious Diseases pays non établi dans la noticeOrganisme public
-
Netherlands Center for Occupational Diseases pays non établi dans la noticeStructure de recherche
-
Amsterdam institute for Infection and Immunity pays non établi dans la noticeStructure de recherche
-
University of Amsterdam Amsterdam UMC pays non établi dans la noticeUniversité ou école supérieure
-
Department of Medicine pays non établi dans la noticeInstitution
-
Section Acute Medicine pays non établi dans la noticeInstitution
Amsterdam Neuroscience, Institute of Infection and Immunity et Office of Infectious Diseases, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.